Orion Oyj マネジメント

マネジメント基準チェック /34

Orion Oyjの CEO はLiisa Hurmeで、 Jan2019年に任命され、の在任期間は 5.83年です。の年間総報酬は€ 819.50Kで、 81.6%給与と18.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.023%を直接所有しており、その価値は$ 1.51M 。経営陣と取締役会の平均在任期間はそれぞれ2年と4.5年です。

主要情報

Liisa Hurme

最高経営責任者

€819.5k

報酬総額

CEO給与比率	81.6%
CEO在任期間	5.8yrs
CEOの所有権	0.02%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Orion Oyj の収益と比較して、Liisa Hurme の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	€332m
Jun 30 2024	n/a	n/a	€232m
Mar 31 2024	n/a	n/a	€217m
Dec 31 2023	€820k	€668k	€217m
Sep 30 2023	n/a	n/a	€173m
Jun 30 2023	n/a	n/a	€306m
Mar 31 2023	n/a	n/a	€336m
Dec 31 2022	€106k	€106k	€350m

報酬と市場: Liisaの総報酬 ($USD 862.72K ) は、 US市場 ($USD 7.90M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Liisaの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Liisa Hurme (57 yo)

5.8yrs

在職期間

€819,500

報酬

Dr. Liisa Hurme, PhD (Biochemistry), has been President , Chief Executive Officer and Chairman of Managemenbt board at Orion Oyj since Novemnber 01, 2022. Dr. Hurme served as Senior Vice President, Global...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Liisa Hurme	President	5.8yrs	€819.50k	0.023% $ 1.5m
Rene Lindell	Chief Financial Officer & Member of Group Executive Management Board	less than a year	データなし	データなし
Olli Huotari	Senior VP of Corporate Functions	22.1yrs	データなし	0.060% $ 3.9m
Satu Ahomäki	Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board	16.8yrs	データなし	0.025% $ 1.6m
Outi Vaarala	Sr. VP of Innovative Medicines	4.4yrs	データなし	0.010% $ 673.8k
Juhani Kankaanpaa	Senior VP of Global Operations & Member of Executive Management Board	2yrs	データなし	0.0036% $ 235.1k
Niclas Lindstedt	Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board	1.8yrs	データなし	0.0031% $ 201.5k
Hao Pan	Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board	1.8yrs	データなし	0.010% $ 685.6k
Julia Macharey	Senior Vice President of People & Culture and Member of Management Board	less than a year	データなし	データなし
Tuukka Hirvonen	Investor Relations & Financial Communications Officer	no data	データなし	データなし
Terhi Ormio	Vice President of Communications	15.6yrs	データなし	データなし
Virve Laitinen	Sr. VP of Corporate Strategy and Program Mgmt. Grp. Level Function & Head of CSPMO	less than a year	データなし	0.023% $ 1.5m

2.0yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: ORIN.Yの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mikael Silvennoinen	Independent Director	10.7yrs	€123.40k	0.0069% $ 456.4k
Veli-Matti Mattila	Independent Chairman	3.7yrs	€61.40k	0.0066% $ 434.7k
Henrik Stenqvist	Director	less than a year	データなし	データなし
Kari Aho	Independent Director	4.5yrs	€61.40k	0.062% $ 4.1m
Ari Lehtoranta	Independent Director	7.7yrs	€72.40k	0.0036% $ 239.1k
Maziar Doustdar	Independent Director	2.7yrs	€60.80k	0.0011% $ 71.1k
Eija Ronkainen	Independent Director	8.7yrs	€61.40k	0.41% $ 27.0m
Hilpi Rautelin	Independent Vice Chairman of the Board	7.7yrs	€81.10k	0.0073% $ 478.8k
Karen Soerensen	Independent Director	2.7yrs	€66.80k	0.0011% $ 71.1k

4.5yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: ORIN.Yの取締役会は経験豊富であると考えられます ( 4.5年の平均在任期間)。

Orion Oyj マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Orion Oyj, Annual General Meeting, Apr 03, 2025

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Recent updates

Orion Oyj Updates Earnings Guidance for the Full Year 2024

Orion Corporation Decides to Terminate the ODM-111 Development Program

Orion Oyj, Annual General Meeting, Apr 03, 2025

Orion Oyj to Report First Half, 2025 Results on Jul 18, 2025

Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint

Orion Oyj Revises Earnings Guidance for the Year 2024

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Orion Oyj Announces CFO Changes

Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database

Orion Corporation Receives Fda Approval for Bonqat (Pregabalin Oral Solution)

Orion Group Appoints Julia Macharey as Senior Vice President, People & Cultur

Orion Oyj to Report Q3, 2024 Results on Oct 29, 2024

Orion Oyj Announces Resignation of Jari Karlson as Chief Financial Officer

Orion Oyj Provides Earnings Guidance for the Year 2023

Orion Oyj Announces Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

Orion Group Provides Earnings Guidance for the Full Year 2022

Orion Group Appoints Liisa Hurme as CEO, Effective 1 January 2023

Orion Oyj Announces Executive Changes

Orion Announces Approval of Additional Indication of Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) from U.S. FDA

Orion Oyj to Report Nine Months, 2023 Results on Oct 26, 2023

Orion Oyj to Report Q1, 2023 Results on Apr 27, 2023

Orion Oyj Revises Earnings Guidance for the Full Year 2022

Orion Oyj to Report Q2, 2022 Results on Jul 15, 2022

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a. from Inovet Bv for €130 million.

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a.from Inovet Bv for €130 million.

Orion Oyj Announces Executive Changes

Orion Oyj Appoints Liisa Hurme as President and the Chair of the Executive Management Board, as of 1 November 2022

Orion’S Collaboration Partner Bayer Submits Applications in the U.S. and Eu for Additional Indication of Darolutamide

Orion Corporation Announces Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Present at ASCO-GU

Orion Oyj Provides Earnings Outlook for the Year 2022

Orion Announces Arasens Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Orion Oyj Provides Earnings Guidance for the Year 2021

Orion Oyj Recalls Multivita Forte Dietary Supplement from Consumers

Orion Animal Health’s Tessie® (tasipimidine) Receives Positive CVMP Opinion

Orion Corporation’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Orion Animal Health’s Bonqat® (Pregabalin) Receives Positive CVMP Opinion

Orion Oyj Provides Earnings Guidance for the Year 2021

Orion Corporation and Bayer Expand Development Program for Darolutamide in Prostate Cancer

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Orion Is Planning to Renew Its R&D Strategy and Organisation

Orion Oyj to Report First Half, 2021 Results on Jul 19, 2021

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34